Reading COCH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track COCH free→Reading COCH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track COCH free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been unsteady, with frequent disruptive corporate changes, and the capital stance is capital unfriendly. Risk is high, and the sector backdrop is a headwind, with the company trading below typical for sector peers. Peer multiples imply a price about 70% below where it trades (it looks expensive on this basis); the read is rich. This assessment is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 1 valuation methods, at three horizons. Current price $0.65. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $0.65, COCH's earnings are too small for P/E to mean much; on sales it trades at 220× p/s (74.9× the 3× p/s peer median). That gap is an optionality premium a financial-multiple model can't price — our $0.38 fair value covers only the as-is business, low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 70% of near-term growth above a flat-multiple fair value; not enough history to forecast a comparison. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only expensive valuation — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.89x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
26 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.00 → $-0.08. 0 raised, 1 cut, 1 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$305.
How much price usually moves either way.
On a bad day, this stock has moved -$788.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,706.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation label changed from 'inexpensive' to 'expensive'.
As of June 16, 2026, the valuation changed, moving from inexpensive to expensive. Risk remained high, and the sector backdrop was noted as a headwind. The company's recent financial performance was described as weak, and earnings quality was characterized as loss-making.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This report will show if the company is moving toward profitability. Investors will look for signs of improvement.
Confirms one read:Earnings report shows a reduction in losses compared to the previous quarter.
Confirms the other:The earnings report shows bigger losses than last quarter.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for COCH yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on November 19, 2025, Envoy Medical, Inc. (the “Company”), received a staff determination notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), informing the Company that its Class A Common Stock, par value $0.0001 per share (the “Common Stock”), had failed to comply with the $1.00 minimum bid price required for con…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
COCH Envoy Medical Inc | Below typical Show detailsSector percentile: 1 of 100 | expensive | high |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 92 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
No qualifying priorities for this snapshot. Check back after the next refresh.
Results of Operations and Financial Condition. On May 11, 2026, Envoy Medical, Inc. (the “Company”), issued a press release regarding the Company’s financial results for its fiscal quarter ended March 31, 2026. A copy of the Company’s press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the accompanying exhibit, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 12, 2026, Envoy Medical, Inc. (the “ Company ”) held its 2026 Annual Meeting of Stockholders (the “ Annual Meeting ”). At the Annual Meeting, the Company’s stockholders (the “ Stockholders ”) approved (the “ Stockholder Approval ”): (i) an amendment to the Company’s 2023 Equity Incentive Plan (the “ Equity Incentive Plan ”) to authorize an a…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers On April 15, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “ Board ”) of Envoy Medical, Inc. (the “ Company ”), the Board appointed Charles S. McKhann to serve as a Class I director, with an initial term expiring at the Company’s 2027 annual meeting of stockholders. In connection with and effective as of his appointment to t…
Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm The Audit Committee (the “ Committee ”) of the Board of Directors of Envoy Medical, Inc. (the “ Company ”) conducted a competitive process to select the audit firm to serve as the Company’s independent registered public accounting firm beginning with the fiscal year ending December 31, 2026. At the conclusion of that process, EisnerAmper LLP (“ EisnerAmper ”) was appointed to serve as…